Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

UPDATE: THE COVID-19 DETECTION FOUNDATION (dba VIRUFY) and 8-03-2023, 21:22

Zonli Announces Product Launch of Summer Bamboo Cooling 21-02-2023, 00:18